SK283872B6 - Farmaceutická kompozícia, spôsob jej prípravy a jej použitie - Google Patents

Farmaceutická kompozícia, spôsob jej prípravy a jej použitie Download PDF

Info

Publication number: SK283872B6
Authority: SK; Slovakia
Prior art keywords: pharmaceutical composition; weight; composition according; fluorophenyl; salt
Prior art date: 2000-01-26

Application number

SK1178-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK11782000A3 (sk

Inventor

Joseph Richard Creekmore

Norman Alfred Wiggins

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-26

Filing date

2000-08-04

Publication date

2004-03-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK283872(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-08-04 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-12-03 Publication of SK11782000A3 publication Critical patent/SK11782000A3/sk

2004-03-02 Publication of SK283872B6 publication Critical patent/SK283872B6/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
238000000034 method Methods 0.000 title claims description 7
238000004519 manufacturing process Methods 0.000 title claims description 4
150000003839 salts Chemical class 0.000 claims abstract description 13
239000004480 active ingredient Substances 0.000 claims abstract 7
239000000203 mixture Substances 0.000 claims description 49
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 28
239000001506 calcium phosphate Substances 0.000 claims description 27
229910000389 calcium phosphate Inorganic materials 0.000 claims description 27
235000011010 calcium phosphates Nutrition 0.000 claims description 27
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 19
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 19
239000008108 microcrystalline cellulose Substances 0.000 claims description 19
229940016286 microcrystalline cellulose Drugs 0.000 claims description 19
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 19
235000019359 magnesium stearate Nutrition 0.000 claims description 17
150000001768 cations Chemical class 0.000 claims description 16
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 15
239000011230 binding agent Substances 0.000 claims description 14
229960001714 calcium phosphate Drugs 0.000 claims description 14
239000004322 Butylated hydroxytoluene Substances 0.000 claims description 13
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 13
229940095259 butylated hydroxytoluene Drugs 0.000 claims description 13
235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 13
239000000945 filler Substances 0.000 claims description 13
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 12
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
239000007884 disintegrant Substances 0.000 claims description 12
239000008101 lactose Substances 0.000 claims description 12
229960001375 lactose Drugs 0.000 claims description 12
239000000314 lubricant Substances 0.000 claims description 11
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
229920003109 sodium starch glycolate Polymers 0.000 claims description 11
239000008109 sodium starch glycolate Substances 0.000 claims description 11
229940079832 sodium starch glycolate Drugs 0.000 claims description 11
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 9
229940057948 magnesium stearate Drugs 0.000 claims description 9
229940069328 povidone Drugs 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
229960000913 crospovidone Drugs 0.000 claims description 6
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 6
229930195725 Mannitol Natural products 0.000 claims description 5
159000000007 calcium salts Chemical class 0.000 claims description 5
239000000594 mannitol Substances 0.000 claims description 5
235000010355 mannitol Nutrition 0.000 claims description 5
229960001855 mannitol Drugs 0.000 claims description 5
239000013543 active substance Substances 0.000 claims description 3
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 3
GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 3
239000004137 magnesium phosphate Substances 0.000 claims description 3
229910000157 magnesium phosphate Inorganic materials 0.000 claims description 3
229960002261 magnesium phosphate Drugs 0.000 claims description 3
235000010994 magnesium phosphates Nutrition 0.000 claims description 3
239000002253 acid Substances 0.000 claims 4
229940009859 aluminum phosphate Drugs 0.000 claims 2
230000006641 stabilisation Effects 0.000 claims 1
238000011105 stabilization Methods 0.000 claims 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 2
230000002035 prolonged effect Effects 0.000 abstract 1
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 1
239000003826 tablet Substances 0.000 description 27
239000003795 chemical substances by application Substances 0.000 description 25
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 8
239000000047 product Substances 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 7
239000011248 coating agent Substances 0.000 description 7
238000000576 coating method Methods 0.000 description 7
150000002596 lactones Chemical class 0.000 description 7
230000003647 oxidation Effects 0.000 description 7
238000007254 oxidation reaction Methods 0.000 description 7
239000008240 homogeneous mixture Substances 0.000 description 6
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 5
229920002678 cellulose Chemical class 0.000 description 5
239000001913 cellulose Chemical class 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
229960001021 lactose monohydrate Drugs 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
-1 7-substituted-3,5-dihydroxy-6-heptenoic acid Chemical class 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
238000002156 mixing Methods 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
229940023144 sodium glycolate Drugs 0.000 description 3
238000005507 spraying Methods 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
235000019700 dicalcium phosphate Nutrition 0.000 description 2
239000001087 glyceryl triacetate Substances 0.000 description 2
235000013773 glyceryl triacetate Nutrition 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
235000013980 iron oxide Nutrition 0.000 description 2
235000019426 modified starch Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
229960002622 triacetin Drugs 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
239000003911 antiadherent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000002576 ketones Chemical group 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229960000292 pectin Drugs 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
238000001782 photodegradation Methods 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1178-2000A 2000-01-26 2000-08-04 Farmaceutická kompozícia, spôsob jej prípravy a jej použitie SK283872B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0001621.2A GB0001621D0 (en)	2000-01-26	2000-01-26	Pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
SK11782000A3 SK11782000A3 (sk)	2001-12-03
SK283872B6 true SK283872B6 (sk)	2004-03-02

Family

ID=9884259

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SK1178-2000A SK283872B6 (sk)	2000-01-26	2000-08-04	Farmaceutická kompozícia, spôsob jej prípravy a jej použitie
SK1179-2000A SK11792000A3 (sk)	2000-01-26	2000-08-04	Farmaceutická kompozícia

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SK1179-2000A SK11792000A3 (sk)	2000-01-26	2000-08-04	Farmaceutická kompozícia

Country Status (48)

Country	Link
US (2)	US6548513B1 (de)
EP (6)	EP1223918B1 (de)
JP (3)	JP3267960B2 (de)
KR (3)	KR100698333B1 (de)
CN (3)	CN1149997C (de)
AP (2)	AP1879A (de)
AR (3)	AR025055A1 (de)
AT (3)	AT412063B (de)
AU (5)	AU738074B2 (de)
BE (2)	BE1013414A5 (de)
BG (4)	BG65234B1 (de)
BR (2)	BR0003364A (de)
CA (3)	CA2313783C (de)
CH (2)	CH700184B1 (de)
CL (1)	CL2007001807A1 (de)
CR (3)	CR6568A (de)
CZ (3)	CZ298411B6 (de)
DE (3)	DE10038110B4 (de)
DK (3)	DK178242B1 (de)
EE (3)	EE05586B1 (de)
ES (2)	ES2155043B1 (de)
FI (3)	FI111806B (de)
FR (2)	FR2804025B1 (de)
GB (3)	GB0001621D0 (de)
HK (4)	HK1048950A1 (de)
HR (3)	HRP20020632B1 (de)
HU (2)	HU222578B1 (de)
IL (4)	IL150513A0 (de)
IS (3)	IS1940B (de)
IT (2)	ITTO20000780A1 (de)
ME (4)	ME00191B (de)
MY (2)	MY122707A (de)
NL (2)	NL1015859C2 (de)
NO (4)	NO327675B1 (de)
NZ (2)	NZ531474A (de)
PL (2)	PL341855A1 (de)
PT (3)	PT102504A (de)
RS (1)	RS50201B (de)
RU (2)	RU2264210C2 (de)
SE (2)	SE523471C2 (de)
SI (1)	SI1223918T1 (de)
SK (2)	SK283872B6 (de)
TR (3)	TR200201888T2 (de)
TW (2)	TW553749B (de)
UA (2)	UA51853C2 (de)
WO (2)	WO2001054669A1 (de)
YU (1)	YU52902A (de)
ZA (2)	ZA200003998B (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
USRE44578E1 (en)	2000-04-10	2013-11-05	Teva Pharmaceutical Industries, Ltd.	Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
CA2406574C (en) †	2000-04-10	2006-12-05	Teva Pharmaceutical Industries, Ltd.	Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) *	2000-08-08	2004-12-24	Smithkline Beecham P	A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
GB0028429D0 (en) *	2000-11-22	2001-01-10	Astrazeneca Ab	Therapy
EP1911462A3 (de) *	2001-01-26	2011-11-30	Schering Corporation	Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
US7883721B2 (en) *	2001-01-30	2011-02-08	Smithkline Beecham Limited	Pharmaceutical formulation
US20050175687A1 (en) *	2001-01-30	2005-08-11	Mcallister Stephen M.	Pharmaceutical formulations
GB0102342D0 (en) *	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
US7842308B2 (en) *	2001-01-30	2010-11-30	Smithkline Beecham Limited	Pharmaceutical formulation
KR20040026705A (ko)	2001-08-16	2004-03-31	테바 파마슈티컬 인더스트리즈 리미티드	스타틴의 칼슘 염 형태의 제조 방법
AU2003254914A1 (en) *	2002-08-12	2004-03-03	Kyowa Hakko Kogyo Co., Ltd.	Amino acid-containing chewable
GB0218781D0 (en) *	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
US20080293750A1 (en) *	2002-10-17	2008-11-27	Anna Helgadottir	Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) *	2002-10-17	2006-01-26	Decode Genetics, Inc.	Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
SI21402A (sl)	2003-02-12	2004-08-31	LEK farmacevtska dru�ba d.d.	Obloženi delci in farmacevtske oblike
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
TW200526274A (en) *	2003-07-21	2005-08-16	Smithkline Beecham Plc	Pharmaceutical formulations
CA2537271A1 (en) *	2003-08-28	2005-03-17	Teva Pharmaceutical Industries, Ltd.	Process for preparation of rosuvastatin calcium
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
PT3395338T (pt) *	2003-09-12	2019-07-23	Amgen Inc	Formulação de dissolução rápida de cinacalcet hcl
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
CA2546701C (en) *	2003-11-24	2010-07-27	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) *	2003-12-02	2012-08-08	特瓦制药工业有限公司	用于表征罗苏伐他汀的参照标准品
US8158362B2 (en) *	2005-03-30	2012-04-17	Decode Genetics Ehf.	Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) *	2004-01-30	2010-08-26	Decode Genetics Ehf.	Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
PE20060003A1 (es) *	2004-03-12	2006-03-01	Smithkline Beecham Plc	Formulacion farmaceutica polimerica para moldear por inyeccion
NZ550942A (en) *	2004-05-04	2011-02-25	Innophos Inc	Directly compressible tricalcium phosphate
GB0411378D0 (en) *	2004-05-21	2004-06-23	Astrazeneca Ab	Pharmaceutical compositions
CN1323665C (zh) *	2004-06-16	2007-07-04	鲁南制药集团股份有限公司	治疗高血脂症的组合物
JP2007508379A (ja) *	2004-07-13	2007-04-05	テバファーマシューティカルインダストリーズリミティド	Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
NZ552390A (en) *	2004-08-06	2010-01-29	Transform Pharmaceuticals Inc	Novel fenofibrate formulations and related methods of treatment
US20070167625A1 (en) *	2005-02-22	2007-07-19	Anna Balanov	Preparation of rosuvastatin
US7612203B2 (en) *	2005-02-22	2009-11-03	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) *	2005-02-22	2007-02-15	Valerie Niddam-Hildesheim	Preparation of rosuvastatin
RU2303980C2 (ru) *	2005-06-03	2007-08-10	ОАО "Щелковский витаминный завод"	Лекарственная форма с антиагрегационным действием и способ ее изготовления
MX2008001597A (es) *	2005-08-04	2008-04-04	Transform Pharmaceuticals Inc	Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
KR20070062996A (ko) *	2005-08-16	2007-06-18	테바 파마슈티컬 인더스트리즈 리미티드	결정성 로수바스타틴 중간체
WO2007031933A2 (en)	2005-09-12	2007-03-22	Actelion Pharmaceuticals Ltd	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007052592A1 (ja) *	2005-10-31	2007-05-10	Kowa Co., Ltd.	光安定性に優れた医薬製剤
WO2007071357A2 (en) *	2005-12-20	2007-06-28	Lek Pharmaceuticals D.D.	Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
HU227696B1 (en) *	2006-04-13	2011-12-28	Egyt Gyogyszervegyeszeti Gyar	Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
EP2024341B1 (de) *	2006-05-03	2015-12-02	MSN Laboratories Private Limited	Neue verfahren für statine und deren pharmazeutisch unbedenkliche salze
HU227610B1 (en) *	2006-09-18	2011-09-28	Richter Gedeon Nyrt	Pharmaceutical compositions containing rosuvastatin potassium
US8404841B2 (en) *	2006-10-09	2013-03-26	Msn Laboratories Limited	Process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008124121A1 (en) *	2007-04-06	2008-10-16	Scidose, Llc	Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124122A1 (en) *	2007-04-09	2008-10-16	Scidose, Llc	Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) *	2007-04-09	2008-10-16	Scidose, Llc	Combinations of statins and anti-obesity agent
CN101336920B (zh) *	2007-07-05	2013-06-05	江苏正大天晴药业股份有限公司	一种稳定的药物组合物
MX2010008466A (es) *	2008-01-30	2010-10-25	Lupin Ltd	Formulaciones de liberación modificada de inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa.
WO2009112870A1 (en) *	2008-03-11	2009-09-17	Belupo-Lijekovi I Kozmetika D.D.	Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
EP2298745B1 (de)	2008-05-27	2014-09-03	Changzhou Pharmaceutical Factory	Verfahren zur herstellung von rosuvastatin-calcium und dessen zwischenprodukten
AU2009256572A1 (en) *	2008-06-13	2009-12-17	Capsugel Belgium Nv	Hydroxypropyl cellulose capsule shell
EP2138165A1 (de) *	2008-06-27	2009-12-30	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmazeutische Zusammensetzung mit einem Statin
SI2309992T1 (en) *	2008-06-27	2018-03-30	Krka, Tovarna Zdravil, D.D., Novo Mesto	A pharmaceutical composition comprising a statin
AU2008358622A1 (en) *	2008-06-27	2009-12-30	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Pharmaceutical compositions of rosuvastatin calcium
PL386051A1 (pl) *	2008-09-09	2010-03-15	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) *	2008-09-30	2018-11-29	EGIS Gyógyszergyár NyR	Stabil kombinációs gyógyszerkészítmény
MX344885B (es) *	2008-11-10	2017-01-10	Psicofarma S A De C V	Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010089770A2 (en)	2009-01-19	2010-08-12	Msn Laboratories Limited	Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (tr)	2009-03-17	2010-01-21	Sanovel İlaç San.Veti̇c.A.Ş.	Stabil rosuvastatin kompozisyonları
US8470805B2 (en) *	2009-04-30	2013-06-25	Kaohsiung Medical University	Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr)	2009-06-03	2010-12-21	Bi̇lgi̇ç Mahmut	Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
WO2011018185A2 (en)	2009-08-13	2011-02-17	Synthon B.V.	Pharmaceutical tablet comprising rosuvastatin calcium
US8987444B2 (en)	2010-01-18	2015-03-24	Msn Laboratories Private Limited	Process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) *	2010-02-09	2011-06-08	鲁南贝特制药有限公司	一种含瑞舒伐他汀钙的片剂及其制备工艺
TR201009397A2 (tr)	2010-11-11	2012-05-21	Bi̇lgi̇ç Mahmut	Rosuvastatin içeren farmasötik bileşimler.
WO2011139256A2 (en)	2010-05-04	2011-11-10	Bilgic Mahmut	Stable rosuvastatin formulations
WO2012027331A1 (en)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh)	2010-11-02	2014-12-01	Univ Kaohsiung Medical	Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
US9399064B2 (en) *	2011-04-12	2016-07-26	Sawai Pharmaceutical Co., Ltd.	Pitavastatin-containing preparation and method for producing same
US20140294959A1 (en) *	2011-05-20	2014-10-02	Astrazeneca Uk Limited	Pharmaceutical Composition of Rosuvastatin Calcium
RU2508109C2 (ru) *	2011-05-27	2014-02-27	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Фармацевтическая композиция для лечения нарушений липидного обмена
DK2851075T3 (da) *	2012-05-14	2022-01-31	Shionogi & Co	Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
AR091706A1 (es) *	2012-07-11	2015-02-25	Teva Pharma	Formulaciones de laquinimod sin agentes alcalinizantes
JP2016514125A (ja)	2013-03-12	2016-05-19	エルジー・ライフ・サイエンシーズ・リミテッドＬＧＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
RO129060B1 (ro)	2013-04-25	2014-11-28	Antibiotice S.A.	Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) *	2013-07-09	2015-04-10	Общество с ограниченной ответственностью "Трейдсервис"	Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko)	2013-07-25	2016-02-23	씨제이헬스케어 주식회사	서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
JP6075818B2 (ja) *	2014-11-11	2017-02-08	塩野義製薬株式会社	光に対して不安定な薬物を含有する多層錠剤
JP2016169198A (ja) *	2015-03-13	2016-09-23	大原薬品工業株式会社	ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) *	2015-04-24	2017-03-15	大原薬品工業株式会社	ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
US11576859B2 (en)	2015-10-23	2023-02-14	Lyndra Therapeutics, Inc.	Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en)	2015-12-08	2017-06-15	Lyndra, Inc.	Geometric configurations for gastric residence systems
EP3243506A1 (de)	2016-05-09	2017-11-15	Adamed sp. z o.o.	Pharmazeutische zusammensetzung
CN109310639A (zh)	2016-05-27	2019-02-05	林德拉有限公司	用于胃驻留系统的材料结构
JP2019532947A (ja)	2016-09-30	2019-11-14	リンドラ，インコーポレイティド	アダマンタン系薬物の持続的送達のための胃内滞留システム
CN107913257A (zh) *	2016-10-10	2018-04-17	北京阜康仁生物制药科技有限公司	一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en)	2016-12-20	2020-03-24	Astrazeneca Uk Ltd.	Systems and methods for dispensing a statin medication over the counter
CA3066658A1 (en)	2017-06-09	2018-12-13	Lyndra, Inc.	Gastric residence systems with release rate-modulating films
JP2018027987A (ja) *	2017-11-24	2018-02-22	共和薬品工業株式会社	医薬組成物
CN112274487A (zh) *	2019-07-25	2021-01-29	北京福元医药股份有限公司	一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) *	2019-10-25	2023-03-28	乐普制药科技有限公司	一种含布立西坦的组合物
US20220008519A1 (en)	2020-07-09	2022-01-13	Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS)	Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en)	2022-09-28	2024-04-03	Novumgen Ltd	A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2262229A (en) *	1939-06-24	1941-11-11	Interchem Corp	Pigment and method of preparation
GB653026A (en)	1947-07-02	1951-05-09	Merck & Co Inc	Vitamin preparations
US4743450A (en)	1987-02-24	1988-05-10	Warner-Lambert Company	Stabilized compositions
US4868185A (en) *	1987-12-10	1989-09-19	Warner-Lambert Company	6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) *	1987-12-10	1990-05-29	Warner-Lambert Company	5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no)	1988-02-25	1989-08-28	Bayer Ag	Substituerte pyrimidiner.
US5030447A (en) *	1988-03-31	1991-07-09	E. R. Squibb & Sons, Inc.	Pharmaceutical compositions having good stability
AU3214689A (en) *	1988-10-06	1990-05-01	Sandoz Ag	Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en)	1989-01-24	1991-04-02	Abbott Laboratories	Stabilizing system for solid dosage forms
US5130298A (en)	1989-05-16	1992-07-14	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
EP0475482B1 (de)	1990-09-13	1994-10-05	Akzo Nobel N.V.	Stabilisierte feste chemische Zusammensetzungen
RU2086544C1 (ru) *	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JP2648897B2 (ja) *	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
RU2098411C1 (ru) *	1991-08-02	1997-12-10	Иституто Лусо Фармако д Италия С.п.А.	Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
HU9203780D0 (en) *	1991-12-12	1993-03-29	Sandoz Ag	Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) *	1992-05-08	1995-12-26	The Green Cross Corporation	Quinoline compounds
JP3254219B2 (ja)	1993-01-19	2002-02-04	ワーナー−ランバート・コンパニー	安定な経口用のｃｉ−９８１製剤およびその製法
US5631365A (en) *	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) *	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
CZ288545B6 (cs) *	1995-12-22	2001-07-11	Kowa Company, Ltd.	Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
DE69713948D1 (de) *	1996-04-23	2002-08-22	Janssen Pharmaceutica Nv	Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
WO1999062560A1 (en)	1998-06-05	1999-12-09	Warner-Lambert Company	Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (sl)	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
GB9900339D0 (en)	1999-01-09	1999-02-24	Zeneca Ltd	Chemical compounds
US6150410A (en)	1999-02-04	2000-11-21	Abbott Laboratories	pH independent extended release pharmaceutical formulation
AR022462A1 (es) *	1999-02-06	2002-09-04	Astrazeneca Uk Ltd	Uso de un agente que disminuye el colesterol
GB0000710D0 (en)	1999-02-06	2000-03-08	Zeneca Ltd	Drug combination
GB0001662D0 (en) *	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
AU3653301A (en)	2000-01-28	2001-08-07	Merck & Co., Inc.	Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

2000
- 2000-01-26 GB GBGB0001621.2A patent/GB0001621D0/en not_active Ceased
- 2000-04-08 UA UA2002021419A patent/UA51853C2/uk unknown
- 2000-08-02 NL NL1015859A patent/NL1015859C2/nl not_active IP Right Cessation
- 2000-08-02 NL NL1015858A patent/NL1015858C2/nl not_active IP Right Cessation
- 2000-08-04 IT IT2000TO000780A patent/ITTO20000780A1/it unknown
- 2000-08-04 DE DE10038110A patent/DE10038110B4/de not_active Expired - Lifetime
- 2000-08-04 US US09/633,114 patent/US6548513B1/en not_active Expired - Fee Related
- 2000-08-04 EE EEP200900047A patent/EE05586B1/xx unknown
- 2000-08-04 WO PCT/GB2000/003017 patent/WO2001054669A1/en not_active Ceased
- 2000-08-04 IL IL15051300A patent/IL150513A0/xx unknown
- 2000-08-04 BE BE2000/0492A patent/BE1013414A5/fr not_active IP Right Cessation
- 2000-08-04 FR FR0010333A patent/FR2804025B1/fr not_active Expired - Lifetime
- 2000-08-04 AU AU51841/00A patent/AU738074B2/en not_active Expired
- 2000-08-04 BR BR0003364-2A patent/BR0003364A/pt active IP Right Grant
- 2000-08-04 EP EP00953283A patent/EP1223918B1/de not_active Expired - Lifetime
- 2000-08-04 SK SK1178-2000A patent/SK283872B6/sk unknown
- 2000-08-04 ES ES200001998A patent/ES2155043B1/es not_active Expired - Fee Related
- 2000-08-04 PL PL00341855A patent/PL341855A1/xx not_active IP Right Cessation
- 2000-08-04 FR FR0010334A patent/FR2795324B1/fr not_active Expired - Lifetime
- 2000-08-04 RS YU5202A patent/RS50201B/sr unknown
- 2000-08-04 AU AU2000264559A patent/AU2000264559A1/en not_active Abandoned
- 2000-08-04 AP APAP/P/2002/002591A patent/AP1879A/en active
- 2000-08-04 MY MYPI20003567A patent/MY122707A/en unknown
- 2000-08-04 SI SI200030065T patent/SI1223918T1/xx unknown
- 2000-08-04 JP JP2000237575A patent/JP3267960B2/ja not_active Expired - Lifetime
- 2000-08-04 TW TW089115660A patent/TW553749B/zh not_active IP Right Cessation
- 2000-08-04 ZA ZA200003998A patent/ZA200003998B/xx unknown
- 2000-08-04 HR HR20020632A patent/HRP20020632B1/xx not_active IP Right Cessation
- 2000-08-04 GB GB0019029A patent/GB2358583B/en not_active Expired - Lifetime
- 2000-08-04 AU AU65800/00A patent/AU6580000A/en not_active Abandoned
- 2000-08-04 ZA ZA200003997A patent/ZA200003997B/xx unknown
- 2000-08-04 ME MEP-2008-338A patent/ME00191B/me unknown
- 2000-08-04 CZ CZ20002884A patent/CZ298411B6/cs not_active IP Right Cessation
- 2000-08-04 EP EP00951701A patent/EP1251831A1/de not_active Withdrawn
- 2000-08-04 CN CNB001224840A patent/CN1149997C/zh not_active Expired - Lifetime
- 2000-08-04 NZ NZ531474A patent/NZ531474A/en not_active IP Right Cessation
- 2000-08-04 DK DK200001171A patent/DK178242B1/da not_active IP Right Cessation
- 2000-08-04 ES ES200001999A patent/ES2171123B1/es not_active Expired - Fee Related
- 2000-08-04 ME MEP-2008-337A patent/ME00202B/me unknown
- 2000-08-04 DK DK200001170A patent/DK200001170A/da not_active Application Discontinuation
- 2000-08-04 YU YU52902A patent/YU52902A/sh unknown
- 2000-08-04 BR BR0003365-0A patent/BR0003365A/pt not_active Application Discontinuation
- 2000-08-04 BE BE2000/0491A patent/BE1013413A3/fr not_active IP Right Cessation
- 2000-08-04 HK HK03101240.3A patent/HK1048950A1/zh unknown
- 2000-08-04 DE DE10038108A patent/DE10038108A1/de not_active Ceased
- 2000-08-04 DK DK00953283T patent/DK1223918T3/da active
- 2000-08-04 KR KR1020000045228A patent/KR100698333B1/ko not_active Ceased
- 2000-08-04 AT AT0136100A patent/AT412063B/de not_active IP Right Cessation
- 2000-08-04 EP EP08165575A patent/EP2018853A1/de not_active Withdrawn
- 2000-08-04 ME MEP-338/08A patent/MEP33808A/xx unknown
- 2000-08-04 PL PL341853A patent/PL196808B1/pl unknown
- 2000-08-04 CH CH01542/00A patent/CH700184B1/de not_active IP Right Cessation
- 2000-08-04 CH CH01541/00A patent/CH691347A5/de not_active IP Right Cessation
- 2000-08-04 FI FI20001749A patent/FI111806B/fi not_active IP Right Cessation
- 2000-08-04 EP EP09171015A patent/EP2133070A1/de not_active Withdrawn
- 2000-08-04 CZ CZ20070222A patent/CZ299105B6/cs not_active IP Right Cessation
- 2000-08-04 FI FI20001750A patent/FI121365B/fi not_active IP Right Cessation
- 2000-08-04 TW TW089115659A patent/TWI228050B/zh not_active IP Right Cessation
- 2000-08-04 CN CNA200710088942XA patent/CN101028268A/zh active Pending
- 2000-08-04 AR ARP000104058A patent/AR025055A1/es unknown
- 2000-08-04 CA CA002313783A patent/CA2313783C/en not_active Expired - Fee Related
- 2000-08-04 ME MEP-337/08A patent/MEP33708A/xx unknown
- 2000-08-04 DE DE60001371T patent/DE60001371T2/de not_active Expired - Lifetime
- 2000-08-04 CN CNB001224859A patent/CN100528161C/zh not_active Expired - Lifetime
- 2000-08-04 EP EP10180659A patent/EP2266540A1/de not_active Withdrawn
- 2000-08-04 EP EP14170807.3A patent/EP2774609A1/de not_active Withdrawn
- 2000-08-04 IT IT2000TO000779A patent/ITTO20000779A1/it unknown
- 2000-08-04 AU AU51842/00A patent/AU781269C/en not_active Revoked
- 2000-08-04 WO PCT/GB2000/003014 patent/WO2001054668A1/en not_active Ceased
- 2000-08-04 CZ CZ20002883A patent/CZ290167B6/cs not_active IP Right Cessation
- 2000-08-04 AT AT00953283T patent/ATE232088T1/de active
- 2000-08-04 IL IL14787000A patent/IL147870A/xx active Protection Beyond IP Right Term
- 2000-08-04 TR TR2002/01888T patent/TR200201888T2/xx unknown
- 2000-08-04 NO NO20003968A patent/NO327675B1/no not_active IP Right Cessation
- 2000-08-04 GB GB0019028A patent/GB2358582B/en not_active Expired - Lifetime
- 2000-08-04 CA CA002315141A patent/CA2315141C/en not_active Expired - Fee Related
- 2000-08-04 PT PT102504A patent/PT102504A/pt active IP Right Grant
- 2000-08-04 MY MYPI20003568 patent/MY123650A/en unknown
- 2000-08-04 TR TR2007/01171T patent/TR200701171T2/xx unknown
- 2000-08-04 HU HU0003110A patent/HU222578B1/hu active IP Right Grant
- 2000-08-04 HR HR20020097A patent/HRP20020097B1/xx not_active IP Right Cessation
- 2000-08-04 US US09/633,064 patent/US6316460B1/en not_active Expired - Lifetime
- 2000-08-04 NZ NZ519774A patent/NZ519774A/en not_active IP Right Cessation
- 2000-08-04 AR ARP000104057A patent/AR023624A1/es unknown
- 2000-08-04 NO NO20003967A patent/NO312434B1/no not_active IP Right Cessation
- 2000-08-04 PT PT102503A patent/PT102503B/pt active IP Right Grant
- 2000-08-04 TR TR2002/00270T patent/TR200200270T2/xx unknown
- 2000-08-04 SE SE0002826A patent/SE523471C2/sv not_active IP Right Cessation
- 2000-08-04 HU HU0003111A patent/HUP0003111A3/hu unknown
- 2000-08-04 HR HR20080525A patent/HRP20080525A2/xx not_active Application Discontinuation
- 2000-08-04 RU RU2002122752/15A patent/RU2264210C2/ru active
- 2000-08-04 EE EEP200200411A patent/EE05221B1/xx unknown
- 2000-08-04 AT AT0136000A patent/AT412062B/de not_active IP Right Cessation
- 2000-08-04 HK HK02108790.3A patent/HK1047052A1/zh unknown
- 2000-08-04 PT PT00953283T patent/PT1223918E/pt unknown
- 2000-08-04 SE SE0002827A patent/SE523481C2/sv not_active IP Right Cessation
- 2000-08-04 RU RU2002103603/14A patent/RU2206324C1/ru active
- 2000-08-04 UA UA2002086973A patent/UA77156C2/xx unknown
- 2000-08-04 JP JP2000237576A patent/JP4800467B2/ja not_active Expired - Lifetime
- 2000-08-04 SK SK1179-2000A patent/SK11792000A3/sk not_active Application Discontinuation
- 2000-08-04 EE EEP200200052A patent/EE04990B1/xx unknown
- 2000-08-04 KR KR10-2000-0045229A patent/KR100388713B1/ko not_active Expired - Lifetime
- 2000-08-04 CA CA2639407A patent/CA2639407C/en not_active Expired - Fee Related
- 2000-08-04 AP APAP/P/2002/002409A patent/AP1449A/en active
2002
- 2002-01-29 IS IS6254A patent/IS1940B/is unknown
- 2002-01-30 CR CR6568A patent/CR6568A/es unknown
- 2002-02-06 BG BG106393A patent/BG65234B1/bg unknown
- 2002-04-17 HK HK02102911.0A patent/HK1040936B/zh not_active IP Right Cessation
- 2002-06-26 CR CR6687A patent/CR6687A/es not_active Application Discontinuation
- 2002-07-01 IL IL150513A patent/IL150513A/en unknown
- 2002-07-16 BG BG106926A patent/BG66168B1/bg unknown
- 2002-07-16 BG BG110353A patent/BG110353A/en unknown
- 2002-07-23 IS IS6480A patent/IS6480A/is unknown
2003
- 2003-04-11 KR KR1020030022854A patent/KR20030036492A/ko not_active Ceased
2005
- 2005-06-02 AU AU2005202392A patent/AU2005202392C1/en not_active Expired
2007
- 2007-03-07 IS IS8620A patent/IS2805B/is unknown
- 2007-03-09 NO NO20071303A patent/NO327554B1/no not_active IP Right Cessation
- 2007-03-12 JP JP2007062353A patent/JP4800988B2/ja not_active Expired - Lifetime
- 2007-03-30 AR ARP070101365A patent/AR060248A2/es unknown
- 2007-06-20 CL CL2007001807A patent/CL2007001807A1/es unknown
- 2007-11-15 IL IL187416A patent/IL187416A0/en unknown
2008
- 2008-06-24 CR CR10114A patent/CR10114A/es not_active Application Discontinuation
2009
- 2009-03-26 BG BG10110353A patent/BG66159B1/bg unknown
2010
- 2010-03-10 NO NO2010005C patent/NO2010005I1/no unknown
- 2010-06-10 FI FI20105657A patent/FI121589B/fi not_active IP Right Cessation
2015
- 2015-02-02 HK HK15101088.4A patent/HK1200368A1/en unknown

Also Published As

Publication number	Publication date
SE0002826L (sv)	2001-07-27
AU738074B2 (en)	2001-09-06
CH700184B1 (de)	2010-07-15
CA2315141C (en)	2009-08-18
IS2805B (is)	2012-09-15
AP1449A (en)	2005-07-28
UA77156C2 (en)	2006-11-15
DE10038110B4 (de)	2006-06-29
GB0019029D0 (en)	2000-09-27
HU0003111D0 (en)	2000-10-28
AU781269C (en)	2006-11-30
SI1223918T1 (en)	2003-06-30
UA51853C2 (uk)	2002-12-16
TR200701171T2 (tr)	2007-04-24
HK1200368A1 (en)	2015-08-07
HK1036934A1 (en)	2002-01-25
FI20105657L (fi)	2010-06-10
FI20001749L (fi)	2001-07-27
IL150513A0 (en)	2003-02-12
CH691347A5 (de)	2001-07-13
BE1013413A3 (fr)	2001-12-04
DK200001171A (da)	2001-07-27
JP2007182452A (ja)	2007-07-19
CZ298411B6 (cs)	2007-09-26
YU52902A (sh)	2006-01-16
IS6480A (is)	2002-07-23
FI111806B (fi)	2003-09-30
HU222578B1 (hu)	2003-08-28
ITTO20000779A0 (it)	2000-08-04
AP2002002409A0 (en)	2002-03-31
TWI228050B (en)	2005-02-21
HRP20080525A2 (en)	2008-12-31
PL341853A1 (en)	2001-01-29
BG106393A (en)	2002-07-31
ITTO20000780A1 (it)	2000-11-04
FR2795324A1 (fr)	2000-12-29
EP1223918A1 (de)	2002-07-24
KR20030036492A (ko)	2003-05-09
CZ299105B6 (cs)	2008-04-23
FR2804025A1 (fr)	2001-07-27
DE60001371T2 (de)	2004-01-22
NL1015859C2 (nl)	2001-10-16
NO20003967D0 (no)	2000-08-04
NO312434B1 (no)	2002-05-13
EP2266540A1 (de)	2010-12-29
FI121365B (fi)	2010-10-29
DK178242B1 (da)	2015-09-28
JP4800988B2 (ja)	2011-10-26
EE04990B1 (et)	2008-04-15
DK200001170A (da)	2001-01-27
SE0002826D0 (sv)	2000-08-04
AP2002002591A0 (en)	2002-09-30
JP2001206847A (ja)	2001-07-31
HRP20020632A2 (en)	2004-12-31
NO2010005I1 (no)	2010-05-03
FR2795324B1 (fr)	2002-05-17
ES2155043A1 (es)	2001-04-16
HRP20020097A2 (en)	2002-06-30
HUP0003111A2 (hu)	2002-02-28
AU2005202392B2 (en)	2008-11-20
FI20001749A0 (fi)	2000-08-04
HK1040936B (zh)	2010-06-11
IS1940B (is)	2004-07-16
BG65234B1 (bg)	2007-09-28
NO327675B1 (no)	2009-09-07
EE200900047A (et)	2011-04-15
RU2002122752A (ru)	2004-03-10
EE200200052A (et)	2003-04-15
NO327554B1 (no)	2009-08-10
HUP0003110A2 (hu)	2001-05-28
IL187416A0 (en)	2008-02-09
HUP0003111A3 (en)	2003-03-28
AR025055A1 (es)	2002-11-06
BG106926A (bg)	2003-04-30
DE60001371D1 (de)	2003-03-13
KR100388713B1 (ko)	2003-06-25
TW553749B (en)	2003-09-21
ATE232088T1 (de)	2003-02-15
BG110353A (en)	2009-09-30
IL147870A0 (en)	2002-08-14
HK1040936A1 (zh)	2002-06-28
EP2133070A1 (de)	2009-12-16
NZ531474A (en)	2007-04-27
CN1149997C (zh)	2004-05-19
RS50201B (sr)	2009-07-15
ZA200003997B (en)	2000-08-14
CA2639407A1 (en)	2001-07-26
CN1319396A (zh)	2001-10-31
ME00202B (me)	2010-10-10
IS8620A (is)	2007-03-07
CZ20002884A3 (cs)	2001-09-12
PL196808B1 (pl)	2008-02-29
ATA13612000A (de)	2004-02-15
IL147870A (en)	2003-10-31
GB2358582B (en)	2004-09-29
CR6687A (es)	2005-07-18
CA2315141A1 (en)	2001-07-26
AU6580000A (en)	2001-08-07
HRP20020632B1 (en)	2010-12-31
HK1047052A1 (zh)	2003-02-07
AU2005202392C1 (en)	2016-06-02
HK1048950A1 (zh)	2003-04-25
CR10114A (es)	2008-08-21
ME00191B (me)	2010-10-10
MY122707A (en)	2006-04-29
DK1223918T3 (da)	2003-04-28
MEP33808A (hr)	2010-10-10
RU2206324C1 (ru)	2003-06-20
CR6568A (es)	2004-03-05
AR023624A1 (es)	2002-09-04
EE05586B1 (et)	2012-10-15
EE05221B1 (et)	2009-10-15
EP2774609A1 (de)	2014-09-10
SE0002827L (sv)	2001-07-27
ZA200003998B (en)	2000-08-14
SE523481C2 (sv)	2004-04-20
FI20001750A0 (fi)	2000-08-04
BE1013414A5 (fr)	2001-12-04
EP1223918B1 (de)	2003-02-05
SK11792000A3 (sk)	2001-12-03
AU5184100A (en)	2001-08-02
ES2155043B1 (es)	2001-12-01
ES2171123B1 (es)	2003-11-16
HU0003110D0 (en)	2000-10-28
BG66159B1 (bg)	2011-09-30
CL2007001807A1 (es)	2008-01-18
HUP0003110A3 (en)	2003-02-28
IL150513A (en)	2012-12-31
GB2358583B (en)	2002-02-06
NO20003967L (no)	2001-07-27
CN101028268A (zh)	2007-09-05
SE523471C2 (sv)	2004-04-20
CA2313783A1 (en)	2000-10-16
TR200201888T2 (tr)	2002-11-21
GB2358582A (en)	2001-08-01
GB0001621D0 (en)	2000-03-15
HK1036935A1 (en)	2002-01-25
AR060248A2 (es)	2008-06-04
FI20001750L (fi)	2001-07-27
NO20003968D0 (no)	2000-08-04
KR100698333B1 (ko)	2007-03-23
SK11782000A3 (sk)	2001-12-03
WO2001054669A1 (en)	2001-08-02
AT412062B (de)	2004-09-27
EE200200411A (et)	2003-12-15
SE0002827D0 (sv)	2000-08-04
NO20071303L (no)	2001-07-27
PT102504A (pt)	2001-07-31
HRP20020097B1 (hr)	2010-12-31
DE10038108A1 (de)	2001-08-02
RU2264210C2 (ru)	2005-11-20
CN100528161C (zh)	2009-08-19
ATA13602000A (de)	2004-02-15
AU781269B2 (en)	2005-05-12
JP4800467B2 (ja)	2011-10-26
NZ519774A (en)	2004-04-30
CN1282581A (zh)	2001-02-07
CA2313783C (en)	2002-03-12
EP1251831A1 (de)	2002-10-30
PT102503B (pt)	2004-02-27
AP1879A (en)	2008-08-14
BR0003365A (pt)	2001-09-18
GB0019028D0 (en)	2000-09-27
JP2001206877A (ja)	2001-07-31
MEP33708A (hr)	2010-10-10
FR2804025B1 (fr)	2002-08-23
YU5202A (sh)	2004-12-31
JP3267960B2 (ja)	2002-03-25
PL341855A1 (en)	2001-07-30
US6316460B1 (en)	2001-11-13
WO2001054668A1 (en)	2001-08-02
IS6254A (is)	2002-01-29
CZ20002883A3 (cs)	2000-10-11
AU5184200A (en)	2001-08-02
AU2005202392A1 (en)	2005-06-30
AU2000264559A1 (en)	2001-08-07
AT412063B (de)	2004-09-27
NL1015858C2 (nl)	2001-07-27
FI121589B (fi)	2011-01-31
GB2358583A (en)	2001-08-01
KR20010077840A (ko)	2001-08-20
NO20003968L (no)	2001-07-27
ES2171123A1 (es)	2002-08-16
CA2639407C (en)	2011-09-13
BG66168B1 (bg)	2011-10-31
NL1015859A1 (nl)	2001-07-27
TR200200270T2 (tr)	2002-06-21
CZ290167B6 (cs)	2002-06-12
PT1223918E (pt)	2003-06-30
BR0003364A (pt)	2001-09-18
PT102503A (pt)	2000-12-29
EP2018853A1 (de)	2009-01-28
US6548513B1 (en)	2003-04-15
KR20000072135A (ko)	2000-12-05
MY123650A (en)	2006-05-31
ITTO20000779A1 (it)	2002-02-04
DE10038110A1 (de)	2001-08-23

Publication	Publication Date	Title
EP1223918B1 (de)	2003-02-05	Pharmazeutische zusammensetzungen enthaltend ein hmg-coa reductase inhibitor
MXPA00007656A (en)	2002-07-25	Pharmaceutical compositions
HK1128409A (en)	2009-10-30	Pharmaceutical compositions comprising a hmg coa reductase inhibitor
HK1139059A (en)	2010-09-10	Pharmaceutical compositions comprising a hmg coa reductase inhibitor
HK1149489A (en)	2011-10-07	Pharmaceutical compositions comprising a hmg coa reductase inhibitor
HK1034673A (en)	2001-11-02	Pharmaceutical compositions